Sarepta falls after-hours on FDA accelerated approval guidance
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics' wild public market ride continues to be bumpy as investors debate whether the US FDA will grant accelerated approval for the company's Duchenne muscular dystrophy (DMD) drug eteplirsen as evidenced by Sarepta's 6.5% decline in after-hours trading on 15 April based on guidance that may cause a delayed early filing.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.